featured
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Cardiology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial
JAMA Cardiol 2019 May 22;[EPub Ahead of Print], SA Murphy, TR Pedersen, ZA Gaciong, R Ceska, MV Ezhov, DL Connolly, JW Jukema, K Toth, MJ Tikkanen, K Im, SD Wiviott, CE Kurtz, N Honarpour, RP Giugliano, AC Keech, PS Sever, MS SabatineFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.